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Longitudinally extensive spinal cord lesions (LECL) restricted to gray matter are poorly
understood as are their neurodevelopmental repercussions in children. We herein report
the critical case of a 13-year-old male presenting with progressive quadriparesis found
to have cervical LECL restricted to the anterior horns. Challenged with a rare diagnostic
dilemma, the clinical team systematically worked through potential vascular, genetic,
infectious, rheumatologic, and paraneoplastic diagnoses before assigning a working
diagnosis of acute inflammatory myelopathy. Nuanced consideration of and workup for
both potential ischemic causes (arterial dissection, fibrocartilaginous embolism, vascular
malformation) and specific inflammatory conditions including Transverse Myelitis,
Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS), Acute
Disseminated Encephalomyelitis (ADEM), and Acute Flaccid Myelitis (AFM) is explained
in the context of a comprehensive systematic review of the literature on previous reports
of gray matter-restricted longitudinally extensive cord lesions in children. Treatment
strategy was ultimately based on additional literature review of treatment-refractory acute
inflammatory neurological syndromes in children. A combination of high-dose steroids
and plasmapheresis was employed with significant improvement in functional outcome,
suggesting a potential benefit of combination immune-modulatory treatment in these
patients. This case furthermore highlights quality clinical reasoning with respect to the
elusive nature of diagnosis, nuances in neuroimaging, and multifocal treatment strategies
in pediatric LECL.
Keywords: myelitis, gray matter, anterior horn, ADEM, acute flaccid myelitis

INTRODUCTION
Longitudinally extensive spinal cord lesions (LECL) are a phenomenon of rapidly progressive
and wide-spread spinal cord inflammation with potentially devastating clinical consequences.
While LECL is best described in the literature as a key diagnostic criterion in Neuromyelitis
Optica Spectrum Disorders (NMOSD), it is also an infrequent, but critical, sequela of a broad
range of inflammatory central nervous system syndromes (1, 2). Inflammatory LECL is most
commonly described as an autoimmune-mediated swelling of myelin sheaths directed by antimyelin basic protein (MBP) antibodies, anti-aquaporin 4 (AQP-4) antibodies, and anti-myelin
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oligodendrocyte glycoprotein (MOG) antibodies, among others
(3). Gray matter involvement in LECL, although rare in early
manifestations of disease, is an acute finding indicative of
either more progressive and refractory presentations of common
autoimmune syndromes (multiple sclerosis, acute disseminated
encephalomyelitis, NMOSD, sarcoidosis), or under-recognized
entities such as pediatric peri-infectious acute flaccid myelitis
(AFM) and paraneoplastic syndromes (4–9).
LECLs demonstrate abnormal hyperintense signal on T2weighted magnetic resonance imaging (MRI) in the spinal cord
that spans at least three vertebral segments (1). Differentiating
between lesions to make a diagnosis can be complicated by the
ambiguity of MRI findings among inflammatory, infectious, and
vascular etiologies. In particular, gray matter-restricted LECL
may closely resemble anterior spinal artery (ASA) infarction,
simulating the “owl’s eye” or “snake eye” appearance on T2weighted axial MRI (10). A prospective study comparing imaging
in early neuromyelitis optica spectrum disorders (NMOSD)
and ASA infarction found that the “owl’s eye” sign tended
to complicate the diagnosis (6). Furthermore, a variable and
indeterminate appearance of centrally located, T2-hyperintense
LECL has been described in both MOG and AQP-4-related
NMOSD, infarction, viral myelitis, sarcoidosis, and spondylitic
compressive myelopathies, and most recently in paraneoplastic
disorders such as GFAP autoimmunity (11–14). In pediatric
patients especially, LECL limited to the gray matter generates
a non-specific differential diagnosis and imparts a risk of
delayed diagnosis and possible long-term morbidity (3, 15, 16).
The following case of a pediatric patient with an acute and
debilitating presentation of LECL sharply restricted to the gray
matter illustrates the importance of a multidisciplinary, clinical
reasoning team approach to diagnosis and treatment in an elusive
and rare pediatric lesion.

At the time of admission, he was hemodynamically stable with
normal vital signs. He was afebrile and in no acute distress. Heart
and lung exams were normal. Neurological exam revealed diffuse
hypotonia, diminished deep tendon reflexes in all extremities,
persistent quadriparesis with most marked weakness in the
radial, median, and ulnar nerve distributions (C5-T1 levels), and
decreased sensation at the C4-L2 levels. Additionally, the patient
had diffuse, severe hyperesthesia in response to sharp stimuli.
There was no evidence of acutely altered mental status, visual or
other cranial nerve deficit, nystagmus, or overt ataxia. Babinski
and Hoffman’s signs were negative and there was no ankle clonus.
There was no spinal or paraspinal tenderness to palpation.

Hospital Course
On hospital day (HD) 1, still unable to support himself while
standing, the patient developed urinary retention requiring
multiple straight catheterizations, representing a symptomatic
nadir 2–3 days after initial symptom onset. He otherwise
remained hemodynamically and neurologically stable during his
stay in the PICU. He showed steady recovery after the following
workup and treatment on HD 3–10 and was discharged to the
Pediatric Acute Rehabilitation Unit on HD 22 in good condition.

Initial Diagnostic Studies
Given the acute nature of the patient’s neurological symptoms,
on HD 1 brain and spine imaging were performed. Brain CT
and MRI were unremarkable—there were no lesions, structural
abnormalities, or edematous changes of the parenchyma or
cranial nerves, and there was no contrast enhancement or
leptomeningeal disease. Total spine MRI, however, showed
a longitudinally extensive, non-enhancing, T2-hyperintense
central cord lesion strictly involving the gray matter from
C2-T2 with mild edema, intervertebral disc intensity changes
in the cervical levels (Figures 1A–C) and robust diffusion
restriction (Figure 1D). These findings were initially thought to
be suggestive of spinal cord infarct, although no abnormal flow
void, cord compression, mass lesion, discrete disc herniation
or desiccation, or other spinal or foraminal stenosis was
noted. Follow-up MRA of the thoracic aorta was inconclusive,
and concern for spinal ischemia necessitated high-resolution
intravascular imaging. On HD 3, interventional angiogram
showed brisk, robust filling and collateralization of the vascular
supply of the spinal cord, and canal after left vertebral artery
injection (Figure 1E). The anterior spinal artery was patent
and of normal caliber. There was no evidence for aortic
dissection or other vascular abnormality. Furthermore, serial
fibrinogen, coagulation, and liver function tests showed no
evidence of coagulopathy.

CASE REPORT
History
A 13-year-old male presented to the Pediatric Emergency
Room at a tertiary care academic medical center due to
progressive quadriparesis that reportedly began after a prolonged
episode of coughing 3 days earlier. His neurological symptoms
manifested as bilateral hand numbness with persistent back
and neck pain, but rapidly progressed to quadriparesis and
widespread tactile and proprioceptive sensory loss over 2 days.
The day prior to his presentation, he was unable to walk
without support. He was subsequently admitted to the Pediatric
Intensive Care Unit (PICU) due to concern for potential rapid
respiratory compromise.
Other than a cough, the patient reported no recent acute
illness and denied travel, trauma, exposures, and vaccinations
(all childhood vaccinations were up to date). Additionally, there
was no history of developmental or cognitive impairment (was
performing well in eighth grade), no drug or alcohol use, and
no history of smoking or e-cigarette use. He had a history of
mild persistent asthma, and his only medication was his albuterol
inhaler that he had been using about twice daily for a week prior
to admission. There were no reported allergies.
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Further Work Up and Treatment
Out of secondary concern for an autoimmune or
infectious etiology, the patient was started on Intravenous
Immunoglobulin (IVIG) (400 mg/kg daily), high-dose steroids
(methylprednisolone 1 g daily), vancomycin, ceftriaxone, and
acyclovir for empiric meningoencephalitis coverage, and aspirin
(81 mg daily) for secondary prevention of possible cord ischemia.
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FIGURE 1 | (A) T2-weighted sagittal admission MRI image of the cervical spine showing longitudinally extensive, non-enhancing, mildly expansile hyperintensity within
the central gray matter of the spinal cord spanning levels C2-T2 with normal appearance of the vertebral flow voids. Mild intervertebral disc intensity changes are
observable at C2-C6. (B,C) Axial T2-weighted MRI images at levels C6 and C8 respectively demonstrating localization of T2-hyperintensity to the anterior horns with
an “owl’s eye” appearance. (D) Diffusion-weighted imaging demonstrating diffusion restriction within the cervical cord lining up with the T2-hyperintense lesion. (E)
Diagnostic angiogram showing the cervical view of the left vertebral artery catheterization. Brisk and robust collateralization to the vascular supply of the spinal cord,
including the anterior spinal artery, and spinal canal is seen. There is no evidence of infarction or dissection of the spinal vasculature.

CSF infectious studies for enterovirus, HSV 1/2, syphilis, Lyme
disease, ehrlichiosis, Cryptococcus, Epstein-Barr virus, and
cytomegalovirus were negative, and serum titers for additional
pathogens including mycoplasma and West Nile virus did
not support acute infection. Additional workup for common
autoimmune myelopathies including neuromyelitis optica
spectrum disorders (NMOSD) and multiple sclerosis (MS) was
non-diagnostic (serum was negative for aquaporin-4 antibodies

Initial laboratory workup, however, was not indicative of an
infectious or an acute inflammatory etiology with a normal
white blood cell count (7.1∗ 103 /µL), negative blood cultures
and respiratory viral panel, and normal sedimentation rate and
C-reactive protein levels (1 mm/h and <0.1mg/L, respectively).
Urine studies, including toxicology, were likewise unremarkable.
Cerebrospinal fluid (CSF) obtained by lumbar puncture also
proved unrevealing (WBC 0, RBC 9, glucose 65, protein 27.3).

Frontiers in Neurology | www.frontiersin.org
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ischemia (reflected by the greatest number of cases in Table 1)
prioritized aortic dissection or other vascular pathology on the
differential. Dissection and vascular malformation were ruled
out by angiogram, but transient ischemic injury from a clot
or fibrocartilaginous embolism dislodged after the prodromal
coughing paroxysm remained under consideration. One of the
largest case series of patients with suspected fibrocartilaginous
embolism reported normal angiography in nearly all patients for
whom imaging was available (37). While no explicit evidence
of disc desiccation or herniation was seen, intervertebral disc
intensity changes in our patient’s cervical spine on T2-weighted
imaging may be suggestive of premature disc disease, a critical
risk factor for fibrocartilaginous embolism (38, 39). Furthermore,
the risk of fibrocartilaginous embolism is thought to be elevated
in children due to increased presence of small spinal arteries
that would allow for retrograde migration of emboli (38, 40).
Our patient’s presentation is also generally congruent with
recently proposed diagnostic criteria for spinal cord infarction:
while symptoms worsened in a stepwise manner over 2–3
days and not within the expected 12 h timeframe, CSF was
non-inflammatory and spinal MRI showed diffusion restriction
without cord compression (41). Although fibrinogen and other
coagulation testing was negative, given the heightened concern
for possible embolic ischemic injury, the patient remained on
aspirin throughout his hospitalization.
Infectious or inflammatory etiologies were also highly
considered, especially since the patient reported recent cough.
Since 2014, the incidence in the United States of a virally-induced
spinal cord disease known as AFM has slowly increased (8).
Much like our patient, AFM presents with acute flaccid limb
weakness following a viral prodrome and MRI findings of LECL
on T2-weighted imaging largely restricted to the anterior horns
with a predilection for the cervical spine (8, 42) Positive serum,
CSF or respiratory viral panel for enteroviruses D68 and 71 are
heavily associated with recent cases, but AFM historically has
been linked to a host of viruses including West Nile, coxsackie,
and adenovirus (8) Furthermore, there are a handful of reports
of a heterogenous entity linking asthma exacerbation and AFM
in children, Hopkins Syndrome, most of which describe similar
imaging findings as in our patient (31, 43, 44). However, in our
patient, a causative viral agent or definitive prodrome was not
identified and therefore a diagnosis of AFM could not be made.
Further workup for a possible inflammatory etiology
included testing for AQP-4 and MOG-associated NMOSD,
multiple sclerosis (MS), and other autoimmune disorders.
MOG antibody-associated myelitis is associated with graymatter restricted T2-signal changes coupled with a lack of
gadolinium enhancement and an AFM-like phenotype, as was
seen in our patient (45). Serum anti-MOG and anti-AQP4
tests, however, were negative and are known to have a high
degree of sensitivity in NMOSD and other anti-MOG syndromes
(46, 47). It is important to note, however, that our patient
received two treatments of intravenous immunoglobulin (IVIG)
prior to AQP-4 and MOG antibody testing, which is known
to diminish test sensitivity (48). Multiple sclerosis (MS), the
most common idiopathic inflammatory neurodegenerative
disease of the central nervous system, was also considered and

(AQP-4) (titer <1:10), myelin oligodendrocyte glycoprotein
antibodies (MOG) (titer <1:10), and CSF was negative for
oligoclonal bands). Serum tests for myositis (aldolase, creatine
kinase) were negative.

Recovery and Follow Up
After two doses of high-dose steroids (total 5 day course) and
IVIG on HD 3–5, the patient’s lower extremity strength began
to improve, urinary retention resolved, and deep tendon reflexes
returned to baseline. Given the negative infectious workup,
antibiotics and acyclovir were discontinued on HD 3. However,
the patient demonstrated a persistent weakness of the bilateral
upper extremities that prompted a 5 day plasmapheresis course
(HD 5–10) as salvage therapy for medically-refractory myelitis.
Over the next few days, the patient achieved significant gains in
strength, sensation, and balance.
The patient was transferred to a pediatric acute rehabilitation
unit on HD 22. His exam remained notable for diminished
hand, wrist, biceps, and triceps strength bilaterally, but he was
able to walk with minimal assistance and his muscle strength
normalized. Sensation was intact in the extremities but remained
slightly diminished in the T4-T10 dermatomes. Paresthesias
were no longer present. At his 3 month follow-up with the
pediatric neurologist, his only residual finding was bilateral hand
weakness, although greatly improved. He was back at school
on a full-day, regular schedule. Diagnosis remained “unspecified
inflammatory spinal cord syndrome.”

DISCUSSION
LECL is a rare phenomenon and presents a critical diagnostic
dilemma in pediatric patients. Possible etiologies for LECL
include traumatic, ischemic, vascular, inflammatory, and
infectious causes or even a genetic polymorphism, each requiring
rapid diagnosis and unique treatment for successful recovery
(17). LECLs are well-described as a characteristic features of
NMOSD. However, in contrast to this patient, the lesions of
NMOSD are typically centrally located, diffuse or patchy, extend
to the medulla, demonstrate contrast enhancement, and are
only rarely seen restricted solely to the anterior horns (18, 19).
Furthermore, most cases of NMOSD and transverse myelitis
are associated with a central, expansive, and contrast-enhancing
lesion (20, 21). Our patient’s presentation was particularly
enigmatic in that his LECL was isolated to the anterior horns
yielding the “owl’s eye” appearance on T2-weighted imaging with
restricted diffusion but without gadolinium enhancement. Initial
unfamiliarity with the potential diagnoses in a non-traumatic
pediatric acute anterior spinal cord myelopathy resulted in
delayed diagnosis and the use of numerous empiric treatments.
A systematic review of PubMed/MEDLINE and EMBASE for
reports sharing MRI findings and pathology consistent with gray
matter-restricted LECL in pediatric patients is shown in Table 1.
The search strategy used in PubMed is defined in Appendix A
and was adapted for EMBASE.
Our patient’s history of a coughing paroxysm, back pain,
and clinician awareness of the more common association of
the “owl’s eye” radiographic sign and restricted diffusion with
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5

8yo M

5yo M

13yo M,
13yo M

Chen
et al. (35)

Wang
et al. (36)

19yo F

Yoder
et al. (34)

Hu
et al. (33)

Subacute onset of bilateral lower extremity
weakness and bowel/bladder incontinence,
meningismus, foot drop, hyperreflexia

Acute asthma exacerbation followed by sudden
onset bilateral lower extremity paralysis
Acute onset lower back pain, paralysis and
numbness of all four extremities, altered mental
status, hyperalgesia, and bladder dysfunction
Hypotonia of lower extremities, loss of lower
extremity reflexes, whole-body paresthesias,
meningismus
Cough, meningismus, altered mental status,
anorexia, abdominal pain, right arm paresthesias,
and areflexia
Hypotonia and areflexia of left upper extremity,
winged left scapula, meningismus

5yo F

Hayashi
et al. (31)
Hsu
et al. (32)

12yo M

Acute onset of fever, tetraparesis and urinary
retention

17yo F

Nelson
et al. (28)

4yo F

12yo F

Elpers
et al. (27)

Girard
et al. (30)

9yo F

Amaral
et al. (26)

4yo M

Left hip pain and weakness, left lower extremity
paresthesias with decreased sensation throughout,
eventually developed flaccid paralysis
Post-viral acute onset of generalized weakness and
meningismus, hypotonia and areflexia of left arm

14yo M

DeSena
et al. (25)

Esposito
et al. (29)

Rapidly progressive flaccid paralysis and burning
pain of the bilateral lower extremities with severe
urinary retention
Headache, somnolence, meningismus, flaccid
paraparesis, pain, and vibratory hypoesthesia at T2,
and cervical adenopathy
Acute onset paresis of left upper extremity and
progressive paresis of left lower extremity with
meningismus and dizziness

8yo F,
8mo F,
12yo F

Post-traumatic acute onset neck pain,
quadriparesis, bladder, and bowel dysfunction
Post-viral acute onset of weakness in of all four
extremities, urinary retention, bowel dysfunction,
T10 sensory level, decreased proprioception
Acute onset neck pain, paresthesias, weakness in
various extremities, decreased tactile sensation,
onset of symptoms post-fall

Symptoms

Reisner
et al. (24)

Ghosh and 10yo M
Mitra (22)
14yo M
Monden
et al. (23)

Age/Gender

Hopkins Syndrome
(enterovirus-D68)
MGUS-associated Transverse
Myelitis

Biotinidase Deficiency (first
misdiagnosed as NMOSD)

LETM with abnormal T2 signal most pronounced in
anterior gray matter with “owl’s eye” appearance

Anti-MOG antibody syndrome

IVIG, Methylprednisolone,
Ciprofloxacin, Ceftriaxone,
Prednisone taper
Methylprednisolone, Plasmapheresis,
IVIG

Ceftriaxone, Acyclovir,
Methylprednisolone, IVIG

IVIG, Methylprednisolone,
Cyclophosphamide, Aspirin

IVIG, Methylprednisolone,
Ampicillin/Sulbactam
Methylprednisolone, Plasmapheresis

Methylprednisolone, Plasmapheresis,
Rituximab, Biotin

Methylprednisolone, Plasmapheresis,
IVIG, Prednisone taper

Spinal Cord Ischemia

AFM (enterovirus-D68)

IVIG, Ganciclovir, Valganciclovir

EBV-related Transverse Myelitis

Methylprednisolone, Prednisone
taper, Cefotaxime, Acyclovir,
Plasmapheresis, Azathioprine,
Rituximab
Dexamethasone, Aspirin,
Methylprednisolone, Vitamin B12

IVIG, High-Dose Steroids,
Cyclophosphamide, Plasmapheresis

Idiopathic Transverse Myelitis

AQP4-Positive NMOSD

Methylprednisolone, Plasmapheresis

Acyclovir, IVIG, Methylprednisolone,
Mannitol boluses

Steroids

Treatment(s)

Fibrocartilaginous Embolism /
Spinal Cord Ischemia

Fibrocartilaginous
Embolism/Spinal Cord Ischemia
ADEM

Diagnosis

SLE
Diffuse swelling and high intensity signal in medulla,
thoracic cord. Owl’s eye sign (bilateral anterior horn
hyperintensities) on T2-weighted image of thoracic cord
T2-hyperintensity of central cervical cord extending up to AFM (enterovirus-D68)
the cervicomedullary junction with subtle involvement of
the pons, midbrain, and cerebellum
T2-hyperintensity of anterior horns from C1-T5
AFM (enterovirus-D68)

Increased T2 signal in anterior cord at T11-L1 with
notable disk extrusion at T10-T11. Focal restricted
diffusion in anterior horns noted
T2-hyperintensity of anterior horns of cervical spinal
cord. Slight enhancement of caudal roots without cord
enhancement
T2-hyperintensity of anterior horns extending from
cervicomedullary junction to T10 without gadolinium
enhancement
T2-hyperintensity of anterior and posterior horns and
edema at T11-L1
Longitudinally-extensive gray matter hyperintensity and
swelling from C3-T1 and in the conus medullaris

Cervical to thoracic spinal cord swelling on T2-weighted
images localized to gray matter with diminished signal in
multiple disc spaces. Restricted diffusion of
T2-hyperintense areas
Increased intramedullary T2 signal localized to anterior
horns from levels T11 to the conus medullaris. Diffuse
enhancement of ventral nerve roots
Hyperintensity in the central cord on T2-weighted
imaging localized to the anterior and lateral horns
spanning T2-T10
Longitudinally-extensive T2-weighted hyperintensity
localized to gray matter from levels C2-T2

T2-hyperintensity of central gray matter from C2-T11
and satellite lesions in the ventral medulla and pons

T2-hyperintensity of anterior horns from levels C3-C8

MRI Findings

TABLE 1 | Previous Reports of Isolated Longitudinally Extensive Gray Matter Cord Lesions in Pediatrics.
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strongly favored methylprednisolone over dexamethasone as
the primary agent (66). In our patient, the urgency of a
rapidly progressive quadriparesis with a likely immune-mediated
etiology demanded adjuvant treatment. IVIG, well-described
in autoantibody-mediated acute inflammatory demyelinating
polyneuropathies, is frequently a first choice for adjuvant
or second-line immunomodulatory therapy in inflammatory
CNS disease (especially in pediatrics) because of its ease
of administration through a peripheral intravenous line and
its high tolerability (67, 68). However, more recent data
suggests that IVIG is inferior to similar treatments in
acute inflammatory myelopathy, such as plasmapheresis or
cyclophosphamide (69, 70).
Additionally, plasmapheresis is acknowledged in the
inflammatory myelopathy literature mostly for its use as
a salvage therapy (71–73). There is increasing evidence,
however, for a synergistic effect of plasmapheresis and
corticosteroids when administered early in the disease
course (70, 74). While the modulatory effect is temporary,
plasmapheresis effectively eliminates pathogenic autoantibodies,
inflammatory cytokines, and complement proteins, thereby
enhancing the longer-lasting molecular and genetic effects
of corticosteroids on macrophage activation and cytokine
production. Targeting both innate and humoral immune
responses with early administration of combination therapy
proved successful in achieving a rapid functional improvement
in our patient.
Multiple large cohort studies in NMOSD patients additionally
support early intervention with apheresis therapies during
flares and found that reduced delay to apheresis improved
the chance of a complete therapeutic response (75, 76). Our
experience and literature review suggest consideration of early
initiation of plasmapheresis in inflammatory LECL, despite
its logistical challenges. Further investigation of the merit of
early combination therapy vs. corticosteroids alone as first-line
treatment is warranted in this context.

can be associated with longitudinally extensive lesions such as
the one in this case in up to 14% of children with MS (3, 49).
However, our patient’s single clinical event with one MRI lesion
demonstrates neither dissemination in space nor time and does
not meet IPMSSG criteria for pediatric multiple sclerosis (50).
Furthermore, the chance that our patient experienced a clinically
isolated syndrome preceding a future diagnosis of MS is <4%
given negative CSF testing for oligoclonal bands (51). Systemic
rheumatologic causes, such as systemic lupus erythematous
(SLE), were ruled out because diagnostic clinical features were
lacking and laboratory testing was negative. Additionally, lack of
contrast enhancement of the LECL on MRI is inconsistent with
the majority of reports of sarcoid myelitis or a covert spondylitic
myelopathy (13, 14).
Acute disseminated encephalomyelitis (ADEM) is a poorly
defined syndrome of multifocal CNS inflammation that
represents 22–32% of acquired monophasic demyelinating
syndromes in children and has a slight male predominance
(52–54). It is a diagnosis of exclusion, and while typically seen as
a post-viral or post-vaccinal syndrome, it can occur in up to 25%
of children with no predisposing history (55). Unlike in most
inflammatory myelopathies, up to 61.5% of ADEM patients have
normal CSF findings, consistent with our patient’s workup (56).
A handful of cases of ADEM isolated to the brainstem and spinal
cord, including one with MRI findings of LECL restricted to the
anterior horns, have been reported (23, 25, 57). Furthermore,
ADEM is known to more often involve the gray matter than
either MS or NMOSD (58). While some key differentiating
features of ADEM such as encephalopathy, multifocal large
brain lesions of the same age, and anti-MOG seropositivity
were not seen in our patient, a diagnosis of spinal-cord isolated
ADEM could not be effectively ruled out (56). Furthermore,
approximately only 40% of ADEM cases demonstrate anti-MOG
seropositivity (and only extremely rare cases have shown AQP-4
seropositivity) (59–61).
In a recent informatics-based study, Barreras et al. describe a
predictive model for determining etiology of myelopathy based
on the time differential from a patient’s symptom onset to
symptom nadir; in our patient’s case, his symptom nadir fell
between 2 and 3 days from symptom onset, placing him at
Barreras’ cutoff between acute and subacute presentations—
supporting our differential diagnosis and suggesting either
an ischemic (acute) or inflammatory (subacute) etiology for
our patients LECL (62). Since AQP-4 and MOG-associated
NMOSD, MS, and systemic autoimmune causes such as SLE
or sarcoidosis were considered unlikely based on imaging and
laboratory testing, clinical management of our patient was
directed by existing evidence for treatment of acute disseminated
encephalomyelitis (ADEM) and other acute inflammatory
myelopathies more generally (while keeping in mind the
possibility of a transient or spontaneously resolving ischemic
etiology and maintaining the patient on aspirin throughout
the admission). High-dose corticosteroids are widely considered
first-line therapy for acute inflammatory central nervous
system processes including ADEM and other autoimmune
myelopathies (63–65). Furthermore, a large observational study
comparing functional outcomes of children with ADEM

Frontiers in Neurology | www.frontiersin.org

CONCLUSION
Swift and accurate diagnosis of the etiology of a T2-hyperintense
gray matter LECL in pediatrics is a complex and critical task.
Systematic literature review supports our experience that while
inflammatory, infectious, and vascular etiologies should all
be considered and worked up, aggressive immunomodulatory
treatment should be maximized early in the disease course,
especially in cases that present a time-consuming diagnostic
challenge. Furthermore, plasmapheresis may contribute to more
comprehensive functional improvement and should be further
explored as part of a primary combination treatment strategy
with high-dose steroids.
This case of LECL restricted to the anterior horns in a
child emphasizes the use of an evidence based, thoughtful
and multidisciplinary clinical reasoning team approach to
inform the diagnosis, work up, and treatment of a rare,
critical and elusive diagnosis in pediatrics where time is of
the essence.
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